Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Heliyon ; 10(4): e25921, 2024 Feb 29.
Article in English | MEDLINE | ID: mdl-38420374

ABSTRACT

Nuclear energy continues to be an important supplier of electricity, but it has problems with waste management and the possibility to leak radioactive material. Iodine, a potentially harmful byproduct of uranium fission, is hazardous to both the environment and human health. Therefore, developing safe, effective, and affordable storage facilities for iodine waste is crucial. Owing to their well-controlled pore structure and substantial certain surface area, covalent organic frameworks (COFs) show promise for the adsorption of radioactive iodine. The newly developed COFs (SJ-COF, YA-COF, and AA-COF) shown amazing properties, including strong thermal and chemical stability, which made them ideal for efficient iodine capture. Notably, the ultrahigh iodine capture capacities of these COFs-8.52 g g-1, 8.12 g g-1 and 7.01 g g-1-were significantly greater than most previously reported materials. And The % removal efficiency for SJ-COF, YA-COF and AA-COF from I2/cyclohexane solutions were 87.9 %, 88.6% and 82.6 % respectively. It is noteworthy that the three COFs have high selectivity, reusability, and iodine retention abilities, maintaining iodine even after five recyclings. Based on the outcomes of the experiments, the adsorption processes of the three COFs were examined, and it was discovered that iodine was bound through physical-chemical adsorption. The findings of our work provide a ground-breaking standard for the removal of nuclear waste and demonstrate the enormous potential of COFs as adaptable porous structures that may be specifically designed to address major environmental concerns.

2.
Chem Biodivers ; 21(4): e202301382, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38366916

ABSTRACT

Cataracts are the leading cause of blindness worldwide, however, there is currently no drug-based treatment. Plants that exhibit antioxidant properties have shown promising anticataract effects, likely because they supplement the activity of glutathione, the major antioxidant in lens cells. An extract of Cleome rupicola, a desert plant found in the United Arab Emirates, has traditionally been used to treat cataracts. Phytochemical screening of the aqueous extract established the presence of flavonoids, tannins, steroid derivatives, and reducing sugars. Fractioning of extracts from the fruits using high-performance liquid chromatography (HPLC) yielded the isolation of the anthelmintic compound cleomin, and its structure was confirmed using mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy.


Subject(s)
Biological Products , Cataract , Cleome , Antioxidants/pharmacology , Antioxidants/analysis , Plant Extracts/pharmacology , Plant Extracts/chemistry , Cleome/chemistry , Fruit/chemistry , Flavonoids/analysis , Chromatography, High Pressure Liquid
3.
Molecules ; 27(19)2022 Oct 09.
Article in English | MEDLINE | ID: mdl-36235244

ABSTRACT

The main protease enzyme (Mpro) of SARS-CoV-2 is one of the most promising targets for COVID-19 treatment. Accordingly, in this work, a structure-based virtual screening of 3.8 million ligand libraries was carried out. After rigorous filtering, docking, and post screening assessments, 78 compounds were selected for biological evaluation, 3 of which showed promising inhibition of the Mpro enzyme. The obtained hits (CB03, GR04, and GR20) had reasonable potencies with Ki values in the medium to high micromolar range. Interestingly, while our most potent hit, GR20, was suggested to act via a reversible covalent mechanism, GR04 was confirmed as a noncompetitive inhibitor that seems to be one of a kind when compared to the other allosteric inhibitors discovered so far. Moreover, all three compounds have small sizes (~300 Da) with interesting fittings in their relevant binding sites, and they possess lead-like characteristics that can introduce them as very attractive candidates for the future development of COVID-19 treatments.


Subject(s)
COVID-19 Drug Treatment , SARS-CoV-2 , Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Catalytic Domain , Coronavirus 3C Proteases , Humans , Ligands , Molecular Docking Simulation , Protease Inhibitors/chemistry
4.
Int J Mol Sci ; 23(8)2022 Apr 18.
Article in English | MEDLINE | ID: mdl-35457286

ABSTRACT

Despite available treatments, breast cancer is the leading cause of cancer-related death. Knowing that the tyrosine phosphatase SHP2 is a regulator in tumorigenesis, developing inhibitors of SHP2 in breast cells is crucial. Our study investigated the effects of new compounds, purchased from NSC, on the phosphatase activity of SHP2 and the modulation of breast cancer cell lines' proliferation and viability. A combined ligand-based and structure-based virtual screening protocol was validated, then performed, against SHP2 active site. Top ranked compounds were tested via SHP2 enzymatic assay, followed by measuring IC50 values. Subsequently, hits were tested for their anti-breast cancer viability and proliferative activity. Our experiments identified three compounds 13030, 24198, and 57774 as SHP2 inhibitors, with IC50 values in micromolar levels and considerable selectivity over the analogous enzyme SHP1. Long MD simulations of 500 ns showed a very promising binding mode in the SHP2 catalytic pocket. Furthermore, these compounds significantly reduced MCF-7 breast cancer cells' proliferation and viability. Interestingly, two of our hits can have acridine or phenoxazine cyclic system known to intercalate in ds DNA. Therefore, our novel approach led to the discovery of SHP2 inhibitors, which could act as a starting point in the future for clinically useful anticancer agents.


Subject(s)
Antineoplastic Agents , Breast Neoplasms , Protein Tyrosine Phosphatase, Non-Receptor Type 11 , Antineoplastic Agents/pharmacology , Breast Neoplasms/drug therapy , Catalytic Domain , Cell Line, Tumor , Enzyme Inhibitors/chemistry , Female , Humans , MCF-7 Cells , Protein Tyrosine Phosphatase, Non-Receptor Type 11/antagonists & inhibitors
5.
Molecules ; 25(18)2020 Sep 20.
Article in English | MEDLINE | ID: mdl-32962260

ABSTRACT

This work demonstrates synthetic strategies for the incorporation of a synthesized pyrimidine glucagon-like peptide-1 (GLP-1) agonist into alginate-coated ZIF-8. The prepared pyrimidine GLP-1 agonist used for the treatment of diabetes type II, was trapped inside polymer coated ZIF-8. The encapsulation of the GLP-1 agonist was confirmed by UV-visible and FT-IR spectroscopies. Furthermore, the release kinetics of GLP-1 agonist drug from alginate-coated ZIF-8 were investigated in phosphate-buffered saline at 37 °C at pH 8 and 1.5. The alginate-coated ZIF-8 exhibited much faster drug release at basic pH than at pH 1.5, indicating the potential of the alginate-coated ZIF-8 system to overcome the fast degradation at acidic pH of the stomach and improve the drug's activity. This study may open the way for the synthesis of new metal organic frameworks (MOFs) to enhance drug delivery systems.


Subject(s)
Alginates/chemistry , Delayed-Action Preparations/chemistry , Drug Carriers/chemistry , Glucagon-Like Peptide-1 Receptor/agonists , Imidazoles/chemistry , Metal-Organic Frameworks/chemistry , Pyrimidines/chemistry , Alginates/metabolism , Blood Glucose/metabolism , Coated Materials, Biocompatible/chemistry , Diabetes Mellitus, Type 2/drug therapy , Drug Compounding , Drug Liberation , Humans , Hydrogen-Ion Concentration , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/pharmacology , Molecular Docking Simulation , Pyrimidines/pharmacology , Zinc/chemistry , Zinc/metabolism
6.
Bioorg Med Chem Lett ; 27(22): 5071-5075, 2017 11 15.
Article in English | MEDLINE | ID: mdl-28988756

ABSTRACT

The therapeutic success of peptide glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of type 2 diabetes mellitus has inspired discovery efforts aimed at developing orally available small-molecule GLP-1 receptor agonists. In this study, two series of new pyrimidine derivatives were designed and synthesized using an efficient route, and were evaluated in terms of GLP-1 receptor agonist activity. In the first series, novel pyrimidines substituted at positions 2 and 4 with groups varying in size and electronic properties were synthesized in a good yield (78-90%). In the second series, the designed pyrimidine templates included both urea and Schiff base linkers, and these compounds were successfully produced with yields of 77-84%. In vitro experiments with cultured cells showed that compounds 3a and 10a (10-15-10-9M) significantly increased insulin secretion compared to that of the control cells in both the absence and presence of 2.8mM glucose; compound 8b only demonstrated significance in the absence of glucose. These findings represent a valuable starting point for the design and discovery of small-molecule GLP-1 receptor agonists that can be administered orally.


Subject(s)
Glucagon-Like Peptide-1 Receptor/agonists , Hypoglycemic Agents/chemical synthesis , Pyrimidines/chemistry , Animals , Cell Line , Glucagon-Like Peptide-1 Receptor/metabolism , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/pharmacology , Insulin/metabolism , Insulin Secretion , Insulin-Secreting Cells/cytology , Insulin-Secreting Cells/drug effects , Insulin-Secreting Cells/metabolism , Mice , Pyrimidines/chemical synthesis , Pyrimidines/pharmacology
7.
Eur J Med Chem ; 136: 270-282, 2017 Aug 18.
Article in English | MEDLINE | ID: mdl-28500995

ABSTRACT

A new series of pyrimidine derivatives 5, 9a-d and 12a-d was synthesized by an efficient procedure. The antibacterial activity of the new compounds was studied against four bacterial strains. Compound 5 was found to exhibit the highest potency, with = 1.0 µg/ml, against both Escherichia coli and Pseudomonas aeruginosa when compared with amoxicillin (MIC = 1.0-1.5 µg/mL). Transmission electron microscope results confirmed that activities against bacteria occurred via rupturing of the cell wall. Molecular modeling results suggested that compounds 5, 9a-d and 12a-d have the potential to irreversibly bind to the penicillin-binding protein (PBP) Ser62 residue in the active site and were able to overcome amoxicillin resistance in bacteria by inhibiting the ß-lactamase enzyme. Docking studies showed that compounds 5, 9a-d and 12a-d inhibit the ß-lactamase enzyme through covalent bonding with Ser70. The synergistic effect with amoxicillin was studied. The newly synthesized compounds reported in this study warrant further consideration as prospective antimicrobial agents.


Subject(s)
Acrylonitrile/pharmacology , Anti-Bacterial Agents/pharmacology , Escherichia coli/drug effects , Pseudomonas aeruginosa/drug effects , beta-Lactamase Inhibitors/pharmacology , beta-Lactamases/metabolism , Acrylonitrile/chemical synthesis , Acrylonitrile/chemistry , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Circular Dichroism , Dose-Response Relationship, Drug , Escherichia coli/enzymology , Magnetic Resonance Spectroscopy , Microbial Sensitivity Tests , Molecular Docking Simulation , Molecular Structure , Pseudomonas aeruginosa/enzymology , Spectrophotometry, Ultraviolet , Structure-Activity Relationship , beta-Lactamase Inhibitors/chemical synthesis , beta-Lactamase Inhibitors/chemistry
8.
Chemistry ; 20(24): 7334-44, 2014 Jun 10.
Article in English | MEDLINE | ID: mdl-24806551

ABSTRACT

Suppression of the dimerization of the viologen radical cation by cucurbit[7]uril (CB7) in water is a well-known phenomenon. Herein, two counter-examples are presented. Two viologen-containing thread molecules were designed, synthesized, and thoroughly characterized by (1)H DOSY NMR spectrometry, UV/Vis absorption spectrophotometry, square-wave voltammetry, and chronocoulometry: BV(4+), which contains two viologen subunits, and HV(12+), which contains six. In both threads, the viologen subunits are covalently bonded to a hexavalent phosphazene core. The corresponding [3]- and [7]pseudorotaxanes that form on complexation with CB7, that is, BV(4+)⊂(CB7)2 and HV(12+)⊂(CB7)6, were also analyzed. The properties of two monomeric control threads, namely, methyl viologen (MV(2+)) and benzyl methyl viologen (BMV(2+)), as well as their [2]pseudorotaxane complexes with CB7 (MV(2+)⊂CB7 and BMV(2+)⊂CB7) were also investigated. As expected, the control pseudorotaxanes remained intact after one-electron reduction of their viologen-recognition stations. In contrast, analogous reduction of BV(4+)⊂(CB7)2 and HV(12+)⊂(CB7)6 led to host-guest decomplexation and release of the free threads BV(2(·+)) and HV(6(·+)), respectively. (1)H DOSY NMR spectrometric and chronocoulometric measurements showed that BV(2(·+)) and HV(6(·+)) have larger diffusion coefficients than the corresponding [3]- and [7]pseudorotaxanes, and UV/Vis absorption studies provided evidence for intramolecular radical-cation dimerization. These results demonstrate that radical-cation dimerization, a relatively weak interaction, can be used as a driving force in novel molecular switches.


Subject(s)
Rotaxanes/chemical synthesis , Cations , Dimerization , Models, Molecular , Molecular Structure , Rotaxanes/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...